Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright

Aclaris Therapeutics (NASDAQ:ACRS)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $16.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 337.16% from the company’s current price. HC Wainwright also issued estimates for Aclaris Therapeutics’ FY2026 earnings at ($0.52) EPS and FY2027 earnings at ($0.55) EPS.

Several other equities research analysts have also recently commented on the company. Craig Hallum assumed coverage on Aclaris Therapeutics in a report on Friday, January 30th. They set a “buy” rating and a $10.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Aclaris Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.80.

Aclaris Therapeutics Stock Down 5.7%

Shares of ACRS opened at $3.66 on Thursday. The firm has a market capitalization of $441.40 million, a PE ratio of -6.91 and a beta of 0.88. The firm has a 50-day moving average price of $3.37 and a 200 day moving average price of $2.75. Aclaris Therapeutics has a 52-week low of $1.05 and a 52-week high of $4.89.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $2.07 million. Aclaris Therapeutics had a negative return on equity of 52.04% and a negative net margin of 829.58%. On average, equities analysts expect that Aclaris Therapeutics will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. ProShare Advisors LLC purchased a new position in Aclaris Therapeutics during the second quarter valued at approximately $26,000. AXQ Capital LP acquired a new stake in shares of Aclaris Therapeutics during the 3rd quarter valued at $27,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Aclaris Therapeutics during the 2nd quarter valued at $28,000. XTX Topco Ltd acquired a new position in shares of Aclaris Therapeutics in the second quarter worth $34,000. Finally, R Squared Ltd purchased a new stake in shares of Aclaris Therapeutics during the fourth quarter worth $37,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.